RAP 0.00% 20.5¢ resapp health limited

Ann: ResApp Provides SMARTCOUGH-C-2 Study Update, page-2

  1. 4,841 Posts.
    lightbulb Created with Sketch. 2369
    The study is recruiting to plan, with 1,277 patients recruited as of 30 May 2018. The incidence of
    the various diseases among study participants has been as expected which should ensure the
    study generates statistically strong results. Independent quality assurance of the cough audio
    recordings has been performed on-site weekly, as per the study protocol, with a sample of the
    audio recordings also being reviewed directly by ResApp. Only approximately 1% of recordings
    have been found in the quality assurance process to be unacceptable.
 
watchlist Created with Sketch. Add RAP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.